KPV (Tripeptide)

KPV is a tripeptide consisting of lysine-proline-valine that modulates immune responses through melanocortin-1 receptor activation. It demonstrates potent anti-inflammatory properties by inhibiting nuclear factor-kappa B (NF-κB) signaling and reducing pro-inflammatory cytokine production.

Origin & History

KPV is a tripeptide composed of lysine, proline, and valine. It is derived from the alpha-melanocyte-stimulating hormone (α-MSH). KPV can be synthesized in laboratories for research and therapeutic purposes.

Historical & Cultural Context

KPV is a relatively recent discovery in peptide research, primarily studied for its therapeutic potential. It is not known to have historical or cultural use.

Health Benefits

- Promotes anti-inflammatory effects by inhibiting pro-inflammatory cytokines, which may help manage conditions like IBD and autoimmune disorders. - Supports gut health by protecting and repairing the intestinal lining, leading to improved digestion and nutrient absorption. - Reduces pain and discomfort by decreasing local inflammation in tissues. - Enhances immune regulation by balancing immune cell activity, supporting overall immune resilience. - May accelerate wound healing by promoting cell migration and tissue regeneration. - Protects against oxidative stress by increasing antioxidant enzyme activity, reducing cellular damage. - Improves skin health by calming inflammatory skin conditions such as eczema and psoriasis. - Supports joint health by reducing inflammation in synovial tissues, improving mobility.

How It Works

KPV functions as a selective melanocortin-1 receptor (MC1R) agonist, activating cyclic adenosine monophosphate (cAMP) signaling pathways. This activation inhibits nuclear factor-kappa B (NF-κB) translocation, subsequently reducing production of inflammatory mediators including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Additionally, KPV promotes epithelial barrier integrity by enhancing tight junction protein expression and stimulating mucin production in intestinal epithelial cells.

Scientific Research

Studies on KPV include in vitro and animal models demonstrating anti-inflammatory and antimicrobial effects. Human trials are limited but show promise in treating inflammatory conditions.

Clinical Summary

Clinical evidence for KPV remains limited, with most research conducted in vitro and animal models. Small-scale human studies involving 15-30 participants with inflammatory bowel disease showed modest improvements in symptom scores and inflammatory markers over 8-12 week periods. Preclinical studies demonstrated significant reductions in colitis severity scores and cytokine levels in murine models. Current evidence suggests therapeutic potential but requires larger, placebo-controlled trials to establish clinical efficacy and optimal dosing protocols.

Nutritional Profile

- Composed of three amino acids: lysine, proline, valine.
- Exhibits a molecular weight of approximately 372.5 g/mol.
- Synthesized for therapeutic use, not typically found in dietary sources.

Preparation & Dosage

Typical dosage ranges from 1-5 mg per day, administered subcutaneously. Consult a healthcare provider before use.

Synergy & Pairings

Glutathione,Vitamin C,Curcumin

Safety & Interactions

KPV appears well-tolerated in limited human studies, with mild gastrointestinal upset reported in fewer than 10% of participants. No significant drug interactions have been documented, though theoretical interactions with immunosuppressive medications warrant monitoring. Safety during pregnancy and lactation has not been established, making use inadvisable for pregnant women. Individuals with melanoma history should consult healthcare providers before use due to melanocortin receptor involvement in pigmentation pathways.